AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00028925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00028925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00028925 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Study NCT03567122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Focus of Attention
Description: Information already included in arm/group descriptions.
Study NCT03567122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Focus of Attention
Description: Information already included in arm/group descriptions.
Study NCT03567122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Information already included in arm/group descriptions.
Study NCT01062906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
Study NCT01062906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
Study NCT03753321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Whey protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
Study NCT03753321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: Soy protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
Study NCT03753321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: Isoenergetic placebo (maltodextrin) for 10 days (7 days pre-loading and 3 days during trials 1 and 2
Study NCT03215641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
Study NCT04784273 — intervention group
Intervention type: PROCEDURE
Intervention: Tibiotalocalcaneal Arthrodesis
Description: Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
Study NCT04784273 — intervention group
Intervention type: DEVICE
Intervention: DynaNail
Description: Utilization of a novel dynamic compression pseudoelastic intramedullary nail
Study NCT01440751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Mitomycin-C (MMC) in trabeculectomy
Description: After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
Study NCT04214444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
Description: The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
Study NCT01379235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilatis exercise
Description: 12 weeks of pilatis exercise 3 times a week.
Study NCT01379235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pilatis exercise
Description: 12 weeks of pilatis exercise 3 times a week.
Study NCT05455463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online aphasia-adapted physical activity class
Description: Online 50-minute physical activity sessions, two to three times weekly for 10-11 weeks. The activity instructions will be modified to be aphasia-friendly (simplified language, multimodality support).
Study NCT02114281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care
Study NCT02114281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not care
Study NCT04106687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Caudal Block
Description: Postoperative pain procedure
Study NCT04106687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral Erector Spinae Block
Description: Postoperative pain procedure
Study NCT04214444 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
Description: The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
Study NCT00383565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT03474601 — intervention group
Intervention type: OTHER
Intervention: Dynamic hormone study and Magnetic resonance imaging
Description: 1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue
Study NCT00698412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cane
Description: This group use the cane every day since the baseline
Study NCT01408108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
Description: A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).
Study NCT01408108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic primary posterior crural repair
Description: Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used).
Study NCT02338258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-rotational plate
Study NCT02338258 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exchanged Intramedullary nailing
Study NCT02338258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exchanged Intramedullary nailing
Study NCT02929290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-9016M
Description: Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day.
Study NCT04288973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microsoft Kinect Detection during mother child interaction
Description: methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
Study NCT03270579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]JNJ-64511070
Description: An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.
Study NCT01759992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold® Inspiratory Muscle Trainer (treatment).
Description: Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
Study NCT03282019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy
Description: Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
Study NCT03282019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy (HOT)
Description: All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
Study NCT03282019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home oxygen therapy (HOT)
Description: All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
Study NCT02455479 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dAd5GNE Vaccine
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
Study NCT02455479 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
Study NCT02193633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014 3 on/4 off & weekly paclitaxel
Description: AZD2014 3 days on, 4 days off + weekly paclitaxel
Study NCT02193633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014 2 on/5 off & weekly paclitaxel
Description: AZD2014 2 days on, 5 Days off + weekly paclitaxel
Study NCT03884231 — intervention group
Intervention type: DEVICE
Intervention: Infinity DBS System with MR Conditional labelling
Description: Patients implanted with the Infinity DBS system with MR Conditional labeling
Study NCT01005771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GF-001001-00
Description: GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
Study NCT01005771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02359149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal injections given by a nurse
Study NCT02359149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injections given by a physician
Study NCT02359149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal injections
Study NCT02359149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injections
Study NCT02359149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF agents
Study NCT02359149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF agents
Study NCT03425136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Description: Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
Study NCT05365074 — intervention group
Intervention type: DRUG
Intervention: Chloroprocaine Injection
Description: Spinal anesthesia with 50 mg of 1% Chloroprocaine
Study NCT02903628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye health education
Description: give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
Study NCT03410485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS index/NoL index
Description: Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55.
Study NCT03410485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variation of baseline mean arterial pressure
Description: Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC.
Study NCT01968005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoreat®(Etodolac-Lidocaine Topical Patch)
Study NCT01968005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02391220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LCA symbiotic fermented milk
Description: LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
Study NCT02391220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: heat-treated fermented milk
Description: heat-treated fermented milk without probiotic cultures and dietary fibres
Study NCT03674606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Description: One 75 mg aspirin dose taken daily
Study NCT03674606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: One 75 mg aspirin dose taken daily
Study NCT03303274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ipsilateral tilt
Description: The operation table will be tilted 20 degrees right laterally.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interstitial lung disease induction algorithm
Description: Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
Study NCT03479879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Estradiol
Study NCT03479879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT03479879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol
Study NCT03479879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol
Study NCT02341170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HS-PCI
Description: Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
Study NCT03802799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYN002 - Cannabidiol Transdermal Gel
Description: Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
Study NCT01520103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorebine, Everolimus
Description: Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
Study NCT01520103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine
Description: Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
Study NCT02094885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioseal Fibrin Sealant
Study NCT02094885 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manual Compression
Study NCT03127163 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraestromal corneal ring
Description: The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
Study NCT03234907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion
Study NCT03234907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion
Study NCT03234907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vedolizumab placebo-matching
Study NCT03234907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vedolizumab placebo-matching
Study NCT04248673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbohydrate reduced bread
Description: Consumption of carbohydrate reduced bread for three months.
Study NCT04248673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate rich bread
Description: Consumption of carbohydrate rich bread for three months.
Study NCT04504669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8701
Description: FOXP3 antisense oligonucleotide
Study NCT04504669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti PDL-1 monoclonal antibody
Study NCT03791060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
Study NCT03720275 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Systematic screening of TTR mutations
Description: The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
Study NCT02822690 — intervention group
Intervention type: OTHER
Intervention: Hospice care at UMCG
Description: introduction of hospice care facilities on the wards at the UMCG
Study NCT02594852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: + laser
Description: Use of laser in the treatment
Study NCT02594852 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: + laser
Description: Use of laser in the treatment
Study NCT02998125 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: prospective assessments for the functional outcome before and after the total knee arthroplasty
Study NCT03325660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration
Description: pelvic floor exercises
Study NCT01459848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: block play
Description: 30 minutes of block play
Study NCT01459848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baby dvd
Description: 30 minutes of dvd viewing
Study NCT02723253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement > 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
Study NCT02723253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tom-OX
Description: The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
Study NCT01877122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proflex® Mesh Mesh implantation
Description: Implantation of mesh in the incision of inguinal area
Study NCT01877122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marlex® Mesh Implant
Study NCT01476358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A (retinyl palmitate).
Description: Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth